Suppr超能文献

接受心脏手术的抗血栓药物治疗患者围手术期出血风险的管理——一项系统综述

Management of perioperative bleeding risk in patients on antithrombotic medications undergoing cardiac surgery-a systematic review.

作者信息

Matejic-Spasic Marijana, Hassan Kambiz, Thielmann Matthias, Geidel Stephan, Storey Robert F, Schmoeckel Michael, Adamson Harriet, Deliargyris Efthymios N, Wendt Daniel

机构信息

CytoSorbents Inc., Monmouth Junction, NJ, USA.

Department of Cardiac Surgery, Asklepios Klinik St. Georg, Hamburg, Germany.

出版信息

J Thorac Dis. 2022 Aug;14(8):3030-3044. doi: 10.21037/jtd-22-428.

Abstract

BACKGROUND

Antithrombotic drugs increase the risk of bleeding, especially in patients who need urgent surgery without an adequate wash-out period. This review aims to evaluate perioperative bleeding complications in patients on dual antiplatelet therapy (DAPT) or direct-acting oral anticoagulants (DOACs) undergoing high-bleeding risk cardiovascular surgery and to present currently available potential solutions to mitigate antithrombotic therapy-related bleeding complications.

METHODS

As a first step, we searched for relevant articles, over the last 10 years, in Medline (PubMed) and abstracted clinical information based on pre-defined criteria for bleeding complications. In the next step, an additional search evaluating potential solutions to mitigate bleeding complications was performed. The literature screening and selection process followed the principles derived from the PRISMA statement.

RESULTS

From all reviewed studies, a total of 19 articles could be included evaluating the risk for bleeding in cardiac surgery related to DAPT or DOACs and 10 papers evaluating antithrombotic drug reversal or removal in the setting of cardiovascular surgery. Reported bleeding rates ranged between 18% and 41%. The variability of the reported data is remarkable. Idarucizumab is reported to provide optimal perioperative hemostasis in up to 93% of patients. It has been observed that andexanet alfa causes unresponsiveness to the anticoagulant effects of heparin. Antithrombotic removal by intraoperative hemoadsorption is found to be associated with a significant decrease in re-thoracotomy rate, overall procedure duration, administered transfusion volumes, chest-tube drainage, and length of hospitalization.

DISCUSSION

Bleeding complications in patients treated with DAPT or DOACs in cardiac surgery are high. New costly reversal agents are available but have not been sufficiently tested in the cardio-surgical setting so far. Interestingly, bleeding-related complications seem to be effectively reduced by applying innovative intraoperative hemoadsorption techniques. Expected results from the ongoing trials should provide better insights concerning the efficacy and safety of several potential solutions. Currently, the variability of reports and the deficit of high-quality studies in this specific setting represent the major limitation for the unbiased conclusion of this review.

摘要

背景

抗血栓药物会增加出血风险,尤其是在那些需要紧急手术且没有足够洗脱期的患者中。本综述旨在评估接受双重抗血小板治疗(DAPT)或直接口服抗凝剂(DOACs)的患者在进行高出血风险心血管手术时的围手术期出血并发症,并介绍目前可用的减轻抗血栓治疗相关出血并发症的潜在解决方案。

方法

第一步,我们在过去10年的医学文献数据库(PubMed)中搜索相关文章,并根据预先定义的出血并发症标准提取临床信息。第二步,进行了一项额外的搜索,评估减轻出血并发症的潜在解决方案。文献筛选和选择过程遵循了源自系统评价和Meta分析的首选报告项目(PRISMA)声明的原则。

结果

在所有综述研究中,共有19篇文章可纳入评估心脏手术中与DAPT或DOACs相关的出血风险,10篇文章评估心血管手术中抗血栓药物的逆转或清除。报告的出血率在18%至41%之间。报告数据的变异性显著。据报道,艾达司珠单抗在高达93%的患者中可提供最佳围手术期止血效果。据观察,阿哌沙班导致对肝素抗凝作用无反应。术中血液吸附清除抗血栓与再次开胸率、总体手术持续时间、输血量、胸管引流量和住院时间的显著减少相关。

讨论

在心脏手术中接受DAPT或DOACs治疗的患者出血并发症发生率很高。新的昂贵的逆转剂已经可用,但到目前为止尚未在心脏手术环境中进行充分测试。有趣的是,应用创新的术中血液吸附技术似乎可以有效减少与出血相关的并发症。正在进行的试验的预期结果应该能提供有关几种潜在解决方案的疗效和安全性的更好见解。目前,在这一特定环境中报告的变异性和高质量研究的不足是本综述得出无偏结论的主要限制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/722a/9442533/8ab29aa7c818/jtd-14-08-3030-f1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验